Author

Seamus E. Degan

University of North Carolina at Chapel HillORCID 0000-0002-8028-2081Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Clint A. StalneckeriD· 2 shared Kirsten L. BryantiD· 2 shared Adrienne D. CoxiD· 1 shared Amber M. AmparoiD· 1 shared Brandon L. MoueryiD· 1 shared Channing J. DeriD· 1 shared Edwin J. IwanowicziD· 1 shared Elisa BaldelliiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Clint A. StalneckerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 29, 2026

Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma

Mallory K. Roach, Seamus E. Degan, Jonathan M. DeLiberty…·Kirsten L. Bryant

This study identifies that vertical inhibition of the autophagy pathway enhances sensitivity to mTORC1 inhibition in PDAC, improving therapeutic efficacy.

DOI 10.64898/2026.06.28.734981

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 3, 2025

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance

Kristina Drizyte‐Miller, Seamus E. Degan, Ryan D. Mouery…·Channing J. Der

This study shows that ONC201 inhibits KRAS-mutant pancreatic cancer growth and overcomes resistance to RAS inhibitors by activating ClpP and altering metabolic pathways.

3 citations

humanexperimental assay

𝕏 PostBluesky